Global General Anesthesia Drugs Market - Growth, Trends, and Forecasts 2017 - 2022

  • ID: 4388621
  • Report
  • Region: Global
  • 122 pages
  • Mordor Intelligence
1 of 3
The global general anesthesia drugs market accounted for USD 3,840 million in 2015 and USD 3,983 million in 2016. The market is expected to reach USD 4,760 million by 2021, growing at a CAGR of 3.6% during the forecast period of 2016 to 2021. General anesthetic drugs suppress central nervous system activity and induce a complete lack of sensation.

Global General Anesthesia Drugs Market-Market Dynamics

The report details several factors driving and restraining the market, some of which are listed below.


Growth in healthcare facilities in emerging economies

Advancement in surgical procedures

Increasing cosmetic and orthopedic surgeries

High incidence of emergency surgical procedures and critical care

New drug approval


The side effects of general anesthetics, lack of skilled anesthesiologist and regulatory issues are turning out to restraints for the market.

The global general anesthesia drugs market has been segmented based on drugs and route of administration. The drugs section is further segmented based on the most used and popular drugs. This includes Sevoflurane, Propofol, Desflurane, isoflurane, Dexmedetomidine, Isoflurane, Midazolam and others. The segment based on the route of administration includes inhalation and injection. Propofol accounts for the largest market share in the global general anesthetic drugs market. Sevoflurane is the largest selling inhalational anesthetic drug. Sevoflurane is gradually replacing the use of Desflurane and Isoflurane.

The segmentation based on geography includes North America, Europe, Asia-Pacific, Middle East and Africa, and South America. North America has been subdivided into the USA, Canada, and Mexico. Europe has been subdivided into the UK, Germany, France, Italy, Spain, and Rest of Europe. The Asia-Pacific market has been subdivided into India, China, Japan, South Korea, Australia & New Zealand and Rest of Asia-Pacific. The Middle East and Africa market has been subdivided into GCC countries, South Africa and Rest of MENA. The South American market has been subdivided into Brazil, Argentina, and Rest of South America. North America accounted for the largest market share of nearly 32% in 2015 and is expected to have similar a market share during the forecast period. In the Asia-Pacific region, China accounted for the largest market share.

Major Companies in the Sector Include:

This Report Offers:

Market analysis for the global general anesthesia drugs market, with region-specific assessments and competition analysis.

Market definition along with the identification of key drivers and restraints.

Identification of factors instrumental in changing the market scenario, rising prospective opportunities, and identification of key companies that can influence this market on a regional scale.

Extensively researched competitive landscape section with profiles of major companies along with their market share.

Identification and analysis of the macro and micro factors that affect the global general anesthesia drugs market.

A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market.

Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped.
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Study deliverables
1.2 Market definition
1.3 Study assumptions
2. Research approach and methodology
2.1 Introduction
2.2 Analysis methodology
2.3 Study timeline
2.4 Study phases
2.4.1 Secondary research
2.4.2 Discussion guide
2.4.3 Market engineering & econometric model
2.4.4 Expert validation
3. Executive summary
4. Key inferences
5. Market overview and industry trends
5.1 Current market scenario
5.2 Porter's five forces
5.2.1 Bargaining power of suppliers
5.2.2 Bargaining power of consumers
5.2.3 Threat to new entrants
5.2.4 Threat to substitute products and services
5.2.5 Competitive rivalry within the industry
6. Market drivers, restraints, challenges, and opportunities
6.1 Market drivers
6.1.1 Rising Number of Surgeries
6.1.2 New approvals of anesthetic drugs
6.1.3 Increase in number of cosmetic surgeries
6.2 Market restraints
6.2.1 Side effects of general anesthetics
6.2.2 Lack of skilled anesthesiologist
6.2.3 Regulatory Issues
6.3 Market opportunities
6.4 Market challenges
7. Market segmentation
7.1 Drugs
7.1.1 Propofol
7.1.2 Sevoflurane
7.1.3 Desflurane
7.1.4 Isoflurane
7.1.5 Dexmedetomidine
7.1.6 Remifentanil
7.1.7 Midazolam
7.1.8 Others
7.2 By route of administration
7.2.1 Inhalation
7.2.2 Injection
8. Market segmentation by geography
8.1 North America
8.1.1 United States
8.1.2 Canada
8.1.3 Mexico
8.2 Europe
8.2.1 Germany
8.2.2 United Kingdom
8.2.3 France
8.2.4 Italy
8.2.5 Spain
8.2.6 Rest of Europe
8.3 Asia-Pacific (APAC)
8.3.1 China
8.3.2 Japan
8.3.3 India
8.3.4 Australia & New Zealand
8.3.5 South Korea
8.3.6 Rest of Asia-Pacific
8.4 Middle East & Africa
8.4.1 GCC
8.4.2 South Africa
8.4.3 Rest of MENA
8.5 South America
8.5.1 Brazil
8.5.2 Argentina
8.5.3 Rest of South America
9. Competitive landscape
9.1 Merger and acquisition analysis
9.2 New Product Launches
9.3 Agreements, Collaborations, and Partnerships
10. Company profiles
10.1 Baxter
10.2 Hospira
10.3 Abbott
10.4 Astra Zeneca
10.5 Roche
10.6 Novartis
10.7 Pfizer
10.8 Eisai
10.9 Fresenius Se & Co.
10.10 Hikma Pharmaceuticals
11. Future outlook for investment opportunity
12. Analyst outlook of the market
Note: Product cover images may vary from those shown
3 of 3


4 of 3
Note: Product cover images may vary from those shown